N@N

Mani Foroohar Maintained (ALNY) at Hold with Decreased Target to $103 on, Feb 11th, 2022

Mani Foroohar of SVB Leerink, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $109 to $103 on, Feb 11th, 2022.

Mani has made no other calls on ALNY in the last 4 months.

There are 9 other peers that have a rating on ALNY. Out of the 9 peers that are also analyzing ALNY, 0 agree with Mani's Rating of Hold.

These are the ratings of the 9 analyists that currently disagree with Mani

---

• Etzer Darout of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $170 on, Thursday, February 3rd, 2022
• Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $350 on, Thursday, January 20th, 2022
• David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $215 on, Tuesday, January 18th, 2022
• Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
• Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
• Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
• Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
• Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
• Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021

Contributing Sources

---